Mr. Zeeshan Saeed reports

FSD PHARMA RETAINS CHRISTIAN ATTAR LAW AND TEAM OF EXPERTS TO LEAD PRELIMINARY INVESTIGATION OF POSSIBLE NAKED SHORT SELLING AND MANIPULATION IN ITS STOCK

FSD Pharma Inc. has retained Christian Attar Law, a regional litigation firm located in Houston, Tex., to co-lead, along with Alan M. Pollack of New York law firm Warshaw Burstein LLP, an investigation of any potential naked short selling or other market manipulation of common shares of FSD Pharma.

The company and its legal team intend to provide all evidence of and records of activity to the appropriate authorities (for example, the Department of Justice, the Securities and Exchange Commission and the Ontario Securities Commission).

About FSD Pharma Inc.

FSD Pharma is a biotechnology company with two candidates in different stages of development. Lucid Psychss Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-MS and Unbuzzd. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. Unbuzzd is a proprietary formulation of natural ingredients, vitamins and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation and restoring normal lifestyle.

We seek Safe Harbor.